As of November 6, 2026, Armata Pharmaceuticals, Inc. is a publicly traded company (NYSE: ARMP). Innoviva, Inc. reports holding 82.7%, a majority of its shares. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, May 13, 2026).
Is this your company?
About to sign with, pay or invest in Armata Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Armata Pharmaceuticals, Inc. a real, registered company?
- Armata Pharmaceuticals, Inc. files with the SEC under CIK 921114 (its SEC filings).
- Its shares are listed under the ticker ARMP on NYSE (SEC company record).
- Incorporated in Washington; business address in Los Angeles, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Armata Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is David House, Chief Financial Officer (Form 8-K filed 2026-07-20). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Innoviva, Inc. (filed 2026-05-13).
Who are Armata Pharmaceuticals, Inc.'s owners and officers?
Armata Pharmaceuticals, Inc.: incorporated in Washington; business address in Los Angeles, California; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-07-20).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-05-13 | Innoviva, Inc. | 82.7% |
| Schedule 13D/A, 2026-01-26 | Innoviva, Inc. | 83.1% |
| Schedule 13D/A, 2025-08-12 | Innoviva, Inc. | 83.3% |
Questions about who owns Armata Pharmaceuticals, Inc.
Who owns Armata Pharmaceuticals, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Armata Pharmaceuticals, Inc.: Innoviva, Inc. (82.7%, Schedule 13D/A, filed 2026-05-13).
When did Innoviva, Inc. buy into Armata Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Innoviva, Inc. on this page is the Schedule 13D/A, filed 2025-08-12, reporting 83.3%; its latest, Schedule 13D/A filed 2026-05-13, reports 82.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Armata Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Armata Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Armata Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-20 | David House | Chief Financial Officer | appointed | 2026-07-17 |
| Form 8-K, 2026-04-27 | Daniel Gilmer | Director | appointed | 2026-04-24 |
Which insiders own Armata Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 198,417 shares (0.53% of shares outstanding) (Form 4, 2026-07-14).
- , the chief business officer: 9,461 shares (0.03% of shares outstanding) (Form 4, 2026-03-17).
Shares outstanding: 37,181,979 as of 2026-08-06, from the company's latest SEC cover page.
How much has Armata Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Armata Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Armata Pharmaceuticals, Inc. and the records around it.
Armata Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Jul 2026
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/armata-pharmaceuticals